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eply
e thank Dr. Opie for his comment on our recent publication (1).
aloric restriction is a powerful tool to reverse at least some of the
egative effects induced by obesity in diabetic patients.
The hypothesis that the effects of the metabolic syndrome arise
rom high levels of circulating fatty acids and cytokines derived
rom (visceral) adipose tissue (2) is indeed supported by our data,
lthough one has to use caution in considering this a causal
elationship, solely based on the present results.
On the other hand, it was recently shown, in another group of
atients with type 2 diabetes, that plasma free fatty acids are, at
east to some extent, involved in the effects of short-term caloric
estriction on the heart (3). We showed that short-term caloric
estriction induced increased levels of free fatty acids and conse-
uently, myocardial triglycerides accumulated. This was associated
ith a change in diastolic function. Interestingly, when this caloric
estriction was combined with administration of the antilipolytic
rug acipimox, these changes were not observed. These results
rovide circumstantial evidence for the relevance of fatty acids in
yocardial triglyceride accumulation and changes in diastolic
unction in this particular group of patients, perfectly in line with
he hypothesis stating the relevance of fatty acids and cytokines
eleased by adipose tissue.
We therefore generally agree with Dr. Opie that our results are
xciting, and they underline the high potential of treatments
iming to decrease adipose tissue compartments to reverse the
ffects of metabolic disease on the heart, whether associated with
atty acids released from adipose tissue or not. cSebastiaan Hammer, MSc
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ultiple Mechanisms
ffect the Clopidogrel Response
e read with interest the paper by Ang et al. (1) in a previous issue
f the Journal. The purpose of the study was to identify factors
ssociated with lower platelet inhibition (PI) with clopidogrel in
atients with cardiovascular disease. Their results showed that
levated plasma fibrinogen 375 mg/dl is a unique factor associ-
ted with lower PI in diabetic patients, whereas increased body
ass index remains independently associated with lower PI after
lopidogrel therapy. They also identify the presence of diabetes
ellitus as a factor associated with lower PI. However, this finding
as only significant in the presence of an elevated serum fibrinogen
evel. No other statistical association with PI was found in the
ultiple variable model.
Although these findings are interesting, other factors involving
lopidogrel response have not been completely evaluated. For exam-
le, the impact of genetic polymorphisms or other genetic factors on
lopidogrel response has not been evaluated in the study. It is well
nown that P2Y12 receptor inhibition is implemented by an active
etabolite of clopidogrel. Therefore, genetic variants of enzymes
ithin the metabolic pathways (P450 enzymes) or downstream targets
f the active metabolite (P2Y, platelet glycoproteins IIb/IIIa and Ia)
ight affect clopidogrel response. Moreover, the metabolic activity of
he P450 enzymes varies considerably among individuals. Genetic
olymorphisms of the cytochrome P450 isoenzymes such as
YP3A4*1B (rs2740574), CYP3A5*3 (rs776746), and CYP2C19*2
rs4244285) have been implicated to modulated individual response to
lopidogrel (2). However, only CYP2C19*2 (SNP rs4244285, AA
